Active Ingredient History
Brentuximab vedotin, sold under the brand name Adcetris, is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seagen in the US. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Antigens, CD (Phase 2)
Burkitt Lymphoma (Phase 1/Phase 2)
Carcinoma (Phase 1)
Carcinoma, Embryonal (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Enteropathy-Associated T-Cell Lymphoma (Phase 2)
Epstein-Barr Virus Infections (Phase 1/Phase 2)
Graft vs Host Disease (Phase 2)
Hematologic Diseases (Phase 2)
HIV (Phase 1)
HIV Infections (Phase 2)
Hyperplasia (Phase 2)
Infectious Mononucleosis (Phase 2)
Intraocular Lymphoma (Phase 1/Phase 2)
Leukemia (Phase 1/Phase 2)
Leukemia, Hairy Cell (Phase 1/Phase 2)
Leukemia, Large Granular Lymphocytic (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Lupus Erythematosus, Systemic (Phase 2)
Lymphatic Diseases (Phase 2)
Lymphoma (Phase 4)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Extranodal NK-T-Cell (Phase 1/Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 1/Phase 2)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoma, T-Cell (Phase 4)
Lymphoma, T-Cell, Cutaneous (Phase 3)
Lymphoma, T-Cell, Peripheral (Phase 2)
Lymphomatoid Granulomatosis (Phase 1/Phase 2)
Lymphomatoid Papulosis (Phase 2)
Lymphoproliferative Disorders (Phase 2)
Melanoma (Phase 2)
Mesothelioma, Malignant (Phase 2)
Mycosis Fungoides (Phase 3)
Myelodysplastic Syndromes (Phase 1)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Plasmacytoma (Phase 2)
Polymorphism, Genetic (Phase 2)
Recurrence (Phase 1)
Safety (Phase 1/Phase 2)
Scleroderma, Diffuse (Phase 2)
Scleroderma, Systemic (Phase 1/Phase 2)
Sclerosis (Phase 2)
Sezary Syndrome (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Testicular Neoplasms (Phase 2)
Transplantation (Phase 1/Phase 2)
Treatment Outcome (Phase 1/Phase 2)
Waldenstrom Macroglobulinemia (Phase 1/Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue